Clinical and biochemical predictors and predictive model of primary aldosteronism

Worapaka Manosroi1*, Natthanan Tacharearnmuang2, Pichitchai Atthakomol3

1 Endocrine and Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Chiang Mai University, Muang Chiang Mai, Chiang Mai, Thailand, 2 Internal Medicine Department, Lee Hospital, Lamphun, Thailand, 3 Orthopedics Department, Faculty of Medicine, Chiang Mai University, Muang Chiang Mai, Chiang Mai, Thailand

* worapaka.m@cmu.ac.th

Abstract

Background

Primary aldosteronism (PA) is the most common cause of secondary hypertension. The diagnosis of PA currently requires multiple complicated measures. The aims of this study were to identify easy-to-obtain clinical and biochemical predictors, and to create predictive model to facilitate the identification of a patient at high risk of having PA.

Materials and methods

This 2-year retrospective cohort study was conducted at a tertiary care medical center. A total of 305 patients who had been tested for plasma aldosterone concentration (PAC) and plasma renin activity (PRA) were identified. Patients with incomplete results of PAC and PRA and those who had an established diagnosis of Cushing's syndrome or pheochromocytoma were excluded. Logistic regression analysis was used to identify significant predictors and to create predictive model of PA.

Results

PA was diagnosed in 128 of the patients (41.96%). Significant predictive factors for PA were age > 60 years (OR 2.12, p = 0.045), female (OR 1.65, p < 0.001), smoking (OR 2.79, p < 0.001), coronary artery disease (OR 2.29, p < 0.001), obstructive sleep apnea (OR 1.50, p = 0.017), systolic blood pressure > 160 mmHg (OR 1.15, p < 0.001), serum potassium < 3 mEq/L (OR 3.72, p = 0.030), fasting blood glucose > 126 mg/dL (OR 0.48, p = 0.001) and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 (OR 1.79, p = 0.001). Predictive model was created with a total score ranged from 0 to 42. A score above 7.5 indicated a higher probability of having PA with a sensitivity of 72% and a specificity of 70%. The diagnostic performance of the predictive model based on area under the curve was 71%.
Conclusions

The clinical and biochemical predictive factors including predictive model identified in this study can be employed as an additional tool to help identify patients at risk of having PA and could help reduce the number of screening and confirmation tests required for PA.

Introduction

The most common cause of secondary hypertension is primary aldosteronism (PA) which accounts for 5 to 10% of hypertensive patients and 20% of resistant hypertensive patients [1]. Diagnosis of this condition is beneficial for patients as this is one of the treatable and curable forms of hypertension [2, 3]. If left undiagnosed or inappropriately treated, PA can result in an increased risk of cardiovascular disease, stroke and other target organ damage compared to essential hypertension [4].

Recent screening guidelines for PA identified various indications which indicate an increased likelihood of PA [5, 6]. The diagnostic procedure for PA involves multiple steps including screening, confirmation, subtype classification and a localization process [5]. Plasma aldosterone concentration (PAC), plasma renin activity (PRA) or direct renin concentration (DRC) are the preferred tests to screen for PA. During the screening process, patients are compelled to discontinue multiple anti-hypertensive medications and close monitoring of blood pressure is required, a complicated procedure which requires professional care. The facilities for laboratory diagnosis may not be available in some institutions. Moreover, in many institutions, there are insufficient trained health-care professionals and endocrinologists to conduct and interpret the tests, interventionists to perform adrenal venous sampling (AVS), and surgeons to perform laparoscopic adrenalectomy. Some patients may need to be referred to another hospital where the resources are accessible, a money- and time-consuming process. Additionally, many of the patients referred to another institution are found to have normal PA screening results.

If easy-to-obtain clinical and biochemical predictive factors for PA could be identified, it could facilitate the diagnosis of PA and also reduce the number of tests for PA screening. To the best of our knowledge, only one study has reported predictive factors and constructed predictive scores for diagnosing PA [7]. Reported factors in that study include age, body mass index (BMI), diabetes status, number of antihypertensive agents taken as well as serum sodium and potassium levels. However, that study used a case detection approach based on the Endocrine Society Clinical Practice Guideline of 2008 which did not include screening of patients with obstructive sleep apnea and hypertension. Those patients are now recommended to be screened for PA in the new 2016 guideline [5, 7, 8].

This study aimed to identify clinical and biochemical predictive factors and to create the predictive model which could facilitate the prediction of PA.

Materials and methods

A 2-year retrospective cohort study was conducted using data acquired from electronic medical records at Maharaj Nakorn Chiang Mai Hospital, a tertiary care hospital in northern Thailand, during December 2017 to December 2019. The inclusion criteria were patient age over 18 years who had been identified for PA screening according to the 2016 Endocrine Society Clinical Practice Guideline, by using plasma aldosterone concentration (PAC) and plasma...
renin activity (PRA), to calculate the aldosterone-renin ratio (ARR) [8]. Indications of PA screening according to that guideline include moderate to severe hypertension, resistant hypertension, hypertension with spontaneous or diuretic-induced hypokalemia, hypertension with adrenal incidentaloma, hypertension and a family history of early-onset hypertension or cerebrovascular disease beginning at age <40 years and hypertension with obstructive sleep apnea (OSA). In our institution, patients in the young population (age <40 years) with hypertension were also routinely screened for PA. Exclusion criteria for this study were patients with incomplete results of PAC and PRA and those who had an established diagnosis of Cushing’s syndrome or pheochromocytoma. Demographic data, indications for screening, clinical presentations and laboratory investigation results were retrieved from hospital medical records and reviewed by the investigators. The study was approved by Chiang Mai University Research Ethic Committee (CMUREC).

**Diagnostic criteria**

Our institution adopted diagnostic criterion of primary aldosteronism from the 2016 Endocrine Society Clinical Practice Guideline. In brief, PAC and PRA are measured with appropriate patient preparation. Positive screening results for PA include the following: (1) ARR >20 (ng/dL)/(ng/mL/hr), (2) PAC levels of >15 ng/dL and (c) PRA <1.0 ng/mL/hr. Those who meet all the screening criteria proceed to confirmation tests unless the patients has either: (1) spontaneous hypokalemia, undetectable PRA and PAC >20 ng/dL, or (2) ARR >100 (ng/dL)/(ng/mL/hr) [8, 9]. Those who have negative screening results and confirmation tests are diagnosed as essential hypertension.

**Aldosterone-renin ratio (ARR) measurement**

Standard procedures for ARR measurement are as follows. Before PAC and PRA are collected, the patient should have a liberal sodium intake and be in a normokalemic state. Antihypertensive medications which interfere with the interpretation of ARR should be discontinued 2–4 weeks before blood is drawn. To maintain optimal blood pressure, antihypertensive medications with less effect on ARR are begun including extended-release verapamil, hydralazine and doxazosin. Blood collection is conducted midmorning after the patients have been upright for at least 2 hours and then seated for 5–15 minutes. The blood is collected in EDTA tubes. PAC and PRA are performed using the enzyme-linked immunoassay method (ELISA) (DIASource Immunoassays®, Nivelles, Belgium) [8]. The intra-assay variability for PAC was 4.7–8.5% and for PRA was 5.3–7.1%.

**Confirmatory tests**

The saline infusion test (SIT) is the confirmation measure employed in our institution. Four liters of 0.9% normal saline are infused intravenously over 4 hours and PAC is collected before and after the infusion. If post-infusion PAC is >10 ng/dL, PA is confirmed. If post-infusion PAC is <5 ng/mL, PA can be ruled out. Repeated SIT are conducted in patients with an equivocal post-infusion PAC number between 5–10 ng/dL. Computerized tomography and adrenal venous sampling are performed to differentiate PA subtypes and to make a distinction between unilateral and bilateral adrenal diseases.

**Definitions**

In this study, moderate to severe hypertension was defined as sustained elevated blood pressure >160/100 mmHg. Resistant hypertension was defined as blood pressure >140/90 mmHg
Statistical analysis

Statistical analysis was performed using the STATA program. The statistical significance was specified as a p-value <0.05 for two-tailed tests. Data are shown as count and percentage or mean and standard deviation (SD) for categorical and continuous data, respectively. Fisher’s exact test and either the t-test or the Mann-Whitney U test were performed for inferential statistics with categorical and continuous data, respectively. Univariable and multivariable analyses of predictive factors for PA were performed using logistic regression analysis clustered by confirmation test and reported as odds ratios (ORs) with a 95% confidence interval. The predictive factors analyzed in the multivariate analysis model were selected based on p-values <0.1 in univariable analysis or on having clinically significant relationship to PA. Stepwise selection with backward elimination by removing variables with p-value >0.2 was conducted to create the final prediction model. Continuous variables were transformed to categorical variables in the final predictive model based on median values. Item scores were calculated by the transformation of the regression coefficient. The coefficient of each level for each factor was divided by the smallest coefficient of the model and rounded to the nearest 0.5. Item scores were then added together to calculate a total score. The total scores were then divided into 2 groups: groups at a low risk and at a high risk of having PA. The cut-off point for the risk levels was retrieved from the level that yielded the highest sensitivity, specificity. To evaluate the performance of the predictive model, the area under the receiver operating characteristics curve (AuROC) was used. Variables with missing data >5% were subjected to multiple imputation regression analysis.

Results

Baseline characteristics of predictive factors associated with primary aldosteronism

Of the 305 patients who were screened for PA, 41.96% (128/305) were diagnosed with PA. Of these, 36.7% (47/128) had an aldosterone-producing adenoma and 63.3% (81/128) had idiopathic bilateral adrenal gland hyperplasia. Males had a non-significantly higher prevalence of PA than females. The overall mean age was 43.14±0.90 years, with the mean age significantly higher in the PA group (47.07±15.79) than in the essential hypertension group (40.30±15.14). A history of smoking was more commonly found in the PA than in the essential hypertension group. Among all patients, the most common indications for PA screening were hypertension in the young (68.52%, 209/305) followed by patients with moderate to severe hypertension (36.39%, 111/305). Among the indications for PA screening, hypertension with hypokalemia and OSA were more commonly documented in PA patients than in the essential hypertension group. In those with PA, proximal muscle weakness was more frequently reported than in the
essential hypertension group. Duration of hypertension was longer in the PA than in the essential hypertension group. Other clinical characteristics, including BMI, co-morbidities, blood pressure level, number of antihypertensive agents and type of anti-hypertensive agents revealed no statistically significant difference between the two groups. Baseline laboratory investigations found a statistically significant lower serum potassium level in the PA than in the essential hypertension group. Other laboratory values showed no statistically significant differences between the groups. Baseline characteristics are shown in Table 1.

Univariate and multivariate logistic regression analysis of predictive factors associated with primary aldosteronism

The predictive factors analyzed in the multivariate analysis model were selected based on p-values < 0.1 in univariable analysis or on having clinically significant relationship to PA. Hypertension in the young as an indication for screening and proximal muscle weakness were not incorporated in the final multivariate model due to redundancy with age and serum potassium level, respectively. Continuous predictive variables were transformed into categorical variables for ease of interpretation. After stepwise backward elimination of predictive factors for PA, nine clinical and laboratory predictors were identified in the final predictive model. Those factors consisted of age > 60 years (OR 2.12, p = 0.045), female (OR 1.65, p<0.001), smoking (OR 2.79, p<0.001), coronary artery disease (OR 2.29, p<0.001), OSA (OR 1.50, p = 0.017), systolic blood pressure > 160 mmHg (OR 1.15, P<0.001), serum potassium < 3 mEq/L (OR 3.72, p = 0.030), fasting blood glucose > 126 mg/dL (OR 0.48, p = 0.001) and eGFR < 60 mL/min/1.73m$^2$ (OR 1.79, p = 0.001). Data are shown in Table 2.

Predictive model

Predictive score was created to predict the probability of patients having PA. The transformed scores ranged from 1.0 to 9.5 with a total score of 42. The scoring system is shown in Table 3. The total scores were classified into two groups: a low-risk group (scores 0–7.5) and a high-risk group (scores above 7.5). This cut-off had a sensitivity and a specificity of 72% and 70%, respectively. The predictive ability of the final model represented by AuROC was 0.71 (95% CI: 0.64–0.77) (Fig 1).

Discussion

The key finding in this study is that nine easy-to-obtain clinical and biochemical factors can facilitate the prediction of PA. The predictive performance of the final predictive model which integrated these factors had acceptable predictive performance based on AuROC.

Our study reported a higher prevalence of PA (41.96%) compared to other studies which reported a prevalence of PA ranging from 5–22% [10, 11]. The elevated prevalence of PA in our study could be related to 1) the broader range of indications for PA screening in our study, which included hypertension in young populations and 2) most of the patients having been referred to the endocrine clinic for PA screening, which could indicate that these patients were already seen as having a high likelihood of having PA. The present study identified five additional predictors: female sex, smoking, having coronary artery disease or OSA and low eGFR. Although in a previous study low BMI, a higher number of anti-hypertensive agents and higher serum sodium (>141 mEq/L) showed statistically significant association with PA, in our study, these factors revealed no significant relationship with PA [7].

Previous studies have reported that PA is generally recognized in middle-aged adults in the third to fifth decades of life. This agrees with the finding from our study that the mean age of patients with PA was approximately 47 years old. Nevertheless, recent evidence suggests that
### Table 1. Baseline characteristics of patients.

| Characteristics                                      | Primary aldosteronism (N = 128) | Essential hypertension (N = 177) | P value |
|------------------------------------------------------|---------------------------------|----------------------------------|---------|
| Demographic data                                     |                                 |                                  |         |
| Female, N (%)                                        | 62 (48.44)                      | 67 (37.85)                       | 0.065   |
| Age in years, mean (±SD)                             | 47.07 (15.79)                   | 40.30 (15.14)                    | <0.001  |
| Age at onset of hypertension in years, mean (±SD)    | 38.46 (1.22)                    | 32.66 (0.95)                     | 0.999   |
| BMI, kg/m², mean (±SD)                               | 26.04 (5.94)                    | 27.81 (6.18)                     | 0.314   |
| Smoking, N (%)                                       | 23 (17.96)                      | 18 (10.16)                       | 0.050   |
| Co-morbidities                                       |                                 |                                  |         |
| Coronary artery disease, N (%)                       | 3 (2.34)                        | 1 (0.56)                         | 0.313   |
| Cerebrovascular disease, N (%)                       | 13 (10.16)                      | 13 (7.34)                        | 0.386   |
| Chronic kidney disease, N (%)                        | 8 (6.25)                        | 10 (5.65)                        | 0.826   |
| Diabetes mellitus, N (%)                             | 14 (10.94)                      | 26 (14.69)                       | 0.338   |
| Hyperlipidemia, N (%)                                | 39 (30.47)                      | 55 (31.07)                       | 0.910   |
| Indications for investigation                        |                                 |                                  |         |
| Hypertension in the young (age < 40 years), N (%)    | 77 (60.16)                      | 132 (74.58)                      | 0.007   |
| Hypertension with hypokalemia, N (%)                 | 58 (45.31)                      | 47 (26.55)                       | 0.001   |
| Hypertension with adrenal incidentaloma, N (%)       | 21 (16.41)                      | 35 (19.77)                       | 0.453   |
| Moderate/severe hypertension, N (%)                  | 48 (37.50)                      | 63 (35.59)                       | 0.733   |
| Resistant hypertension, N (%)                        | 4 (3.12)                        | 3 (1.69)                         | 0.418   |
| Hypertension with obstructive sleep apnea, N (%)     | 29 (16.38)                      | 12 (9.38)                        | 0.077   |
| Clinical manifestations                              |                                 |                                  |         |
| Proximal muscle weakness, N (%)                      | 14 (10.94)                      | 9 (5.08)                         | 0.056   |
| Headache, N (%)                                      | 36 (28.13)                      | 52 (29.38)                       | 0.812   |
| No symptoms, N (%)                                   | 80 (62.5)                       | 118 (66.67)                      | 0.452   |
| Hypertension                                        |                                 |                                  |         |
| Duration of hypertension (years) median (IQR)        | 7 (4–11)                        | 6 (3–11)                         | 0.089   |
| Systolic blood pressure (mmHg) mean (±SD)            | 147.97 (17.21)                  | 147.50 (17.49)                   | 0.880   |
| Diastolic blood pressure (mmHg) mean (±SD)           | 89.70 (16.66)                   | 89.37 (13.41)                    | 0.097   |
| Treatment                                            |                                 |                                  |         |
| Number of antihypertensive drugs, mean (IQR)         | 2 (1–3)                         | 2 (1–2)                          | 0.448   |
| < 3 drugs, N (%)                                     | 92 (71.88)                      | 136 (76.84)                      | 0.325   |
| ≥ 3 drugs, N (%)                                     | 36 (28.12)                      | 41 (23.16)                       |         |
| Type of antihypertensive drugs                       |                                 |                                  |         |
| ACEI/ARBs, N (%)                                     | 51 (39.84)                      | 72 (40.68)                       | 0.883   |
| Alpha-blocker, N (%)                                 | 28 (21.88)                      | 35 (19.77)                       | 0.655   |
| Beta-blocker, N (%)                                  | 25 (19.53)                      | 28 (15.82)                       | 0.398   |
| Calcium channel blocker, N (%)                       | 107 (83.59)                     | 143 (80.79)                      | 0.530   |
| Thiazide diuretics, N (%)                            | 11 (8.59)                       | 12 (6.78)                        | 0.554   |
| Loop diuretics, N (%)                                | 0                               | 2 (1.13)                         | 0.511   |
| Spironolactone, N (%)                                | 6 (4.69)                        | 3 (1.69)                         | 0.173   |
| Vasodilator, N (%)                                   | 25 (19.53)                      | 39 (22.03)                       | 0.596   |
| Lab investigations                                   |                                 |                                  |         |
| Sodium, mmol/L, mean (±SD)                           | 140.23 (3.08)                   | 139.50 (2.68)                    | 0.306   |
| Potassium, mmol/L, mean (±SD)                        | 3.51 (0.56)                     | 3.77 (0.48)                      | 0.064   |
| Bicarbonate, mmol/L, mean (±SD)                      | 25.08 (3.17)                    | 24.33 (2.53)                     | 0.174   |
| Plasma aldosterone concentration, ng/dL, median (IQR)| 36.94 (21.58–65.90)            | 18.00 (11.48–31.12)              | <0.001  |
| Plasma renin activity, ng/mL/hr, median (IQR)        | 0.29 (0.13–0.71)                | 1.34 (0.61–3.09)                 | <0.001  |

(Continued)
PA is becoming more common in the elderly (age over 65 years) \[12, 13\]. Likewise, our study found that age over 60 years is one of the risk factors related to PA, with a risk 2.12 times than in younger people (aged <40 years). This could result from increased salt sensitivity in the elderly as well as a decrease in PRA from lower production and an increase in PAC from autonomous secretion of aldosterone by aldosterone-producing cell clusters. These factors can lead to relatively high ARR and may result in an increased diagnostic prevalence of PA \[13–15\]. However, recent evidence suggests that the ARR cut-off for the elderly and extreme elderly should be adjusted to higher values \[16\], although this recommendation has not yet been endorsed in the most recent guideline.

Regarding the association of gender and PA, the present study showed that being female tended to increase PA risk by 1.65 times compared to males. This finding is similar to other studies which have reported that the prevalence of PA tends to be higher in females than in males. However, in those studies after adjusting for confounders, being female represented no statistically significant increased risk of PA compared to males \[7, 17\]. Another study reported that female gender is one of the predictors of bilateral adrenal hyperplasia (the predominant subtype identified in our study) \[18\]. However, there was also evidence that estrogen status or

### Table 2. Univariable and multivariable logistic regression analyses of predictive factors related to primary aldosteronism.

| Predictor                        | Crude odds ratio | 95% CI       | p-value | Adjusted odds ratio | 95% CI       | p-value |
|----------------------------------|------------------|--------------|---------|---------------------|--------------|---------|
| Age >60 years                    | 2.34             | 1.25–4.38    | 0.008   | 2.12                | 1.01–4.42    | 0.045   |
| Female                           | 1.54             | 0.91–2.60    | 0.091   | 1.65                | 1.01–4.42    | <0.001  |
| BMI >25                          | 0.63             | 0.38–1.01    | 0.060   | 1.65                | 1.01–4.42    | <0.001  |
| Smoking                          | 1.92             | 1.11–3.32    | 0.018   | 2.79                | 1.50         | <0.001  |
| Duration of hypertension >6 years| 1.40             | 1.39–1.41    | <0.005  | 2.29                | 1.57–3.35    | <0.001  |
| Coronary artery disease          | 4.22             | 2.82–6.31    | <0.005  | 2.29                | 1.57–3.35    | <0.001  |
| Obstructive sleep apnea          | 1.89             | 0.87–4.08    | 0.104   | 1.50                | 1.07–2.10    | 0.017   |
| ≥3 antihypertensive medications  | 1.29             | 0.87–1.91    | 0.189   | 2.29                | 1.57–3.35    | <0.001  |
| Proximal muscle weakness         | 2.29             | 0.45–11.52   | 0.314   | 1.50                | 1.07–2.10    | 0.017   |
| Systolic blood pressure >160 mmHg| 0.96             | 0.57–1.61    | 0.880   | 1.15                | 1.13–1.16    | <0.001  |
| Diastolic blood pressure >100 mmHg| 1.10            | 0.57–2.14    | 0.766   | 1.15                | 1.13–1.16    | <0.001  |
| Potassium <3 mEq/L               | 3.54             | 1.80–7.04    | <0.001  | 3.72                | 1.13–12.16   | 0.030   |
| Sodium >140 mEq/L                | 1.82             | 0.64–5.14    | 0.256   | 1.15                | 1.13–1.16    | <0.001  |
| Bicarbonate >24 mEq/L            | 1.26             | 0.42–3.76    | 0.678   | 1.15                | 1.13–1.16    | <0.001  |
| Fasting blood glucose >126 mg/dl  | 0.73             | 0.33–1.61    | 0.440   | 1.15                | 1.13–1.16    | <0.001  |
| Total cholesterol >200 mg/dl     | 0.99             | 0.61–1.61    | 0.97    | 1.15                | 1.13–1.16    | <0.001  |
| eGFR <60 mL/min/1.73m²           | 2.46             | 1.17–5.19    | 0.017   | 1.79                | 1.59–2.02    | 0.001   |

https://doi.org/10.1371/journal.pone.0272049.t002
The menstrual phase in females can cause a false-positive for direct renin concentration (DRC), but not for PRA, which was the main test in our study [19].

The present study demonstrated that hypokalemia (<3 mEq/L) and moderate to severe hypertension (systolic blood pressure >160 mmHg) are significant predictors for PA, a finding supported by multiple studies. Approximately 30% of patients with PA have hypokalemia [20]. As to the relationship with hypertension, the prevalence of PA was found to increase with the severity of hypertension—8% in moderate hypertension and 13% in severe hypertension [21]. These factors have been included as indications for PA screening in multiple guidelines [5, 8].

Coronary artery disease, OSA and chronic kidney disease (low eGFR) are linked to the pathophysiology of PA by various mechanisms. Increased aldosterone levels in PA patients can activate proinflammatory and oxidative stress and can have profibrotic effects on the vessels contributing to cardiovascular disease [22]. Higher prevalence of OSA in PA patients has been reported to be around 60–70% [23]. The Endocrine Society Guideline also suggests screening for PA in all hypertensives with OSA, suggesting a bidirectional relationship between PA and OSA. Increased aldosterone causes rise in salt and water retention resulting in parapharyngeal edema and worsening of OSA. On the other hand, intermittent hypoxia from chronic OSA leads to increased sympathetic nerve activity and can activate the renin-angiotensin-aldosterone system [24]. In chronic kidney disease, increased aldosterone can

| Predictor                                      | β-coefficient | Item score | Assigned score |
|------------------------------------------------|---------------|------------|---------------|
| Age >60 years                                  |               |            |               |
| Yes                                            | 0.75          | 5.35       | 5.5           |
| No                                             |               | 0          |               |
| Sex                                            |               |            |               |
| Female                                         | 0.47          | 3.35       | 3.5           |
| Male                                           |               | 0          |               |
| Smoking                                        |               |            |               |
| Yes                                            | 0.79          | 5.64       | 5.5           |
| No                                             |               | 0          |               |
| Coronary artery disease                        |               |            |               |
| Yes                                            | 0.77          | 5.5        | 5.5           |
| No                                             |               | 0          |               |
| No obstructive sleep apnea                     |               |            |               |
| Yes                                            | 0.37          | 2.64       | 2.5           |
| No                                             |               | 0          |               |
| Systolic blood pressure > 160 mmHg             |               |            |               |
| Yes                                            | 0.14          | 1          | 1             |
| No                                             |               | 0          |               |
| Potassium <3 mEq/L                             |               |            |               |
| Yes                                            | 1.33          | 9.5        | 9.5           |
| No                                             |               | 0          |               |
| Fasting blood glucose ≤126 mg/dL               |               |            |               |
| Yes                                            | 0.73          | 5.21       | 5             |
| No                                             |               | 0          |               |
| eGFR <60 mL/min/1.73m²                         |               |            |               |
| Yes                                            | 0.55          | 3.92       | 4             |
| No                                             |               | 0          |               |

https://doi.org/10.1371/journal.pone.0272049.t003
damage small and medium vessels and cause nephropathy [25]. Moreover, a study demonstrated that administration of a mineralocorticoid antagonist can improve kidney function and reduce proteinuria in PA patients [26].

Our study revealed that current smokers had a higher risk of having PA. Cigarette smoking could be linked with PA indirectly. Patients with PA who are current smokers may have a higher risk of cardiovascular events caused by increased oxidative stress resulting in endothelial injury [27]. However, a direct association between cigarette smoking and PA has not yet been demonstrated. In fact, a prior study that evaluated risk factors for PA reported that patients’ smoking status had no significant association with PA [28]. The underlying factors related to this issue needed to be explored further.

In a prospective study by German cohort, diabetes and metabolic syndrome were found to be significantly more prevalent in PA than in a matched control population. For that reason, at first we hypothesized that diabetes could be one of the positive predictors of PA. Interestingly, in our cohort fasting study, blood glucose >126 mg/dL had a negative predictive effect on PA (OR 0.48). This unexpected result is similar to that reported by Kietsiriroje et al. [7]. The hypothesis behind our unanticipated finding, is that diabetes can lead to atherosclerosis, thus
resulting in a high prevalence of essential hypertension in patients with co-existing diabetes. The prevalence of diabetes in PA patients has been reported to be 17.2% to 23% [29, 30] which is lower than in essential hypertension which has been reported as 16.9–41.9%. This report supported our hypothesis [31].

The present study demonstrated that there is a statistically significant association among easily accessible clinical and biochemical factors and the risk of having PA. The final predictive model combining these factors provided acceptable diagnostic performance. The results help suggest when a clinician should refer a patient for PA screening, especially in institutions where investigative resources are not available. In the future, creation of a predictive risk scoring system would make the system more practical.

The associations between the predictors and PA identified in this study could be explained by underlying physiology and the evidence already presented. To reduce the occurrence of bias, possible confounding factors have been adjusted for in the multivariable model and the criteria for definitive diagnosis of PA as well as other key aspects have been defined. Additionally, cluster analysis was performed to reduce variation in the confirmation tests. A strict criterion for PA diagnosis, i.e., PAC levels >15 ng/dL, was employed to reduce the incidence of false positive diagnoses of PA based on a very low PRA. The relatively large sample size in this study provided sufficient power of analysis.

There are some limitations in this study. First, this is a retrospective and single-center study, a potential source of selection bias which could limit the applicability of the results to other institutions. Second, hypertension in the young population was included as one of the indications for PA screening in our cohort even though this has not been established elsewhere in the standard guidelines. This issue could have had the effect of reducing the incidence of PA identified in our cohort as most of the young (<40 years) patients were diagnosed with essential hypertension. Third, the sample size was not calculated prior to the analysis. However, backward calculation for the power of analysis showed a power of > 0.80 which indicated an adequate sample size to interpret the results. Lastly, some predictors, e.g. young age at onset of hypertension and multiple anti-hypertensive medications used, were not significantly related to PA in our proposed model. These predictors had been reported in multiple studies with the strong associations with PA [32, 33]. Therefore, we recommend that this predictive model should be employed as a supplementary tool to facilitate the diagnosis of PA.

Conclusions

Numerous clinical and laboratory investigations can facilitate the prediction of PA. This predictive model can be used as an additional tool to allow the physicians in institutions where resources for investigating PA are not readily accessible to decide which patients needed to be referred. Using these predictors could result in time- and cost-savings as the number of PAC, PRA and confirmation tests can be reduced. External validation in future research should be accomplished to confirm the predictive ability of this model.

Acknowledgments

The authors are grateful to Dr. Lamar G. Robert and Dr. Chongchit A. Robert for reviewing the manuscript.

Author Contributions

Data curation: Natthanan Tacharearnmuang.

Formal analysis: Worapaka Manosroi, Natthanan Tacharearnmuang, Pichitchai Atthakomol.
Methodology: Worapaka Manosroi, Pichitchai Atthakomol.

Supervision: Worapaka Manosroi.

Writing – original draft: Natthanan Tacharearnmuang.

Writing – review & editing: Worapaka Manosroi.

References

1. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension (Dallas, Tex: 1979). 2002; 40(6):892–6. https://doi.org/10.1161/01.hyp.0000040261.30455.b6 PMID: 12468575

2. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. The Journal of clinical endocrinology and metabolism. 2004; 89(3):1045–50. https://doi.org/10.1210/jc.2003-031337 PMID: 15001583

3. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology. 2006; 48(11):2293–300. https://doi.org/10.1016/j.jacc.2006.07.059 PMID: 17161262

4. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaia F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. The lancet Diabetes & endocrinology. 2018; 6(1):41–50. https://doi.org/10.1016/S2213-8587(17)30319-4 PMID: 29129575

5. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. The case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2008; 93(9):3266–81. https://doi.org/10.1210/jc.2008-0104 PMID: 18552288

6. Rossi GP, Bisogni V, Bacca AV, Belfiore A, Cesari M, Concistrè A, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology Hypertension. 2020; 5:100029. https://doi.org/10.1016/j.ijchy.2020.100029 PMID: 33447758

7. Kietsiriroje N, Wonghirunde cha R, Suntornloh anakul O, Murray RD. Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism. Clin Endocrinol (Oxf). 2020; 92(3):196–205.

8. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2016; 101(5):1889–916.

9. Maiolino G, Rossitto G, Bisogni V, Cesari M, Scaccia TM, Plebani M, et al. Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. J Am Heart Assoc. 2017; 6(5). https://doi.org/10.1161/JAHA.117.005574 PMID: 28529209

10. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020; 173(1):10–20. https://doi.org/10.7326/M20-0065 PMID: 32448886

11. Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens. 2011; 2011:162804–. https://doi.org/10.4061/2011/162804 PMID: 21837271

12. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. Journal of the American College of Cardiology. 2017; 69(14):1811–20. https://doi.org/10.1016/j.jacc.2017.01.052 PMID: 28385310

13. Nakama C, Kamide K, Kawai T, Hongyo K, Ito N, Onishi M, et al. The influence of aging on the diagnosis of primary aldosteronism. Hypertension research: official journal of the Japanese Society of Hypertension. 2014; 37(12):1062–7.

14. Käyser SC, Deinum J, de Grauw WJ, Schalk BW, Bor HJ, Lenders JW, et al. Prevalence of primary aldosteronism in primary care: a cross-sectional study. The British journal of general practice: the journal of the Royal College of General Practitioners. 2018; 68(667):e114–e22. https://doi.org/10.3399/bjgp18X694589 PMID: 29335324

15. Mulatero P, Burrello J, Williams TA, Monticone S. Primary Aldosteronism in the Elderly. The Journal of clinical endocrinology and metabolism. 2020; 105(7). https://doi.org/10.1210/clinem/dgaa206 PMID: 32903754
16. Cesari M, Secchia TM, Maiolino G, Rossi GP. Primary aldosteronis m in elderly, old, and very old patients. Journal of human hypertens ion. 2020; 34(12):807–13. https://doi.org/10.1038/s41371-020-00395-2 PMID: 32929132

17. Käyser SC, Deinum J, de Grauw WJ, Schalk BW, Bor HJ, Lenders JW, et al. Prevalence of primary aldosteron ism in primary care: a cross-sectional study. The British journal of general practice: the journal of the Royal College of General Practitioners. 2018; 68(667):e114–e22. https://doi.org/10.3399/ bjgp18X694589 PMID: 29335324

18. Kobayashi H, Abe M, Soma M, Takeda Y, Kurihara I, Itoh H, et al. Development and validation of sub-type prediction scores for the workup of primary aldosteronism. J Hypertens. 2018; 36(11):2269–76. https://doi.org/10.1097/HJH.0000000000001855 PMID: 30020243

19. Ahmed AH, Gordon RD, Ward G, Wolley M, McWhinney BC, Ungerer JP, et al. Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women. J Clin Endocrino Metab. 2017; 102(7):2329–34. https://doi.org/10.1210/jc.2016-3851 PMID: 28379474

20. Gruber S, Beuschlein F. Hypokalem ia and the Prevalence of Primary Aldosteronis m. Horm Metab Res. 2020; 52(6):347–56. https://doi.org/10.1055/a-1134-4980 PMID: 32252108

21. Calhoun DA. Aldoster onism and hypertens ion. Clin J Am Soc Nephrol. 2006; 1(5):1039–45. https://doi.org/10.2215/CJN.01060306 PMID: 17699324

22. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond). 2007; 113(6):267–78. https://doi.org/10.1042/CS20070123 PMID: 17683282

23. Wolf J, Narkiewic z K. Primary Aldosteronism and Obstructive Sleep Apnea: A Cross-Sectio nal Multi-Ethnic Study. Hypertens ion. 2019; 74(6):1305–6. https://doi.org/10.1161/HYPERTENSIONAHA.119.13935 PMID: 31679428

24. Loh HH, Sukor N. Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we know so far? J Hum Hypertens. 2020; 34(1):5–15. https://doi.org/10.1038/s41371-019-0294-8 PMID: 31822780

25. Hollenbe rg NK. Aldostero ne in the developme nt and progress ion of renal injury. Kidney Int. 2004; 66 (1):1–9. https://doi.org/10.1111/j.1523-1755.2004.00701.x PMID: 15200407

26. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. Jama. 2006; 295(22):2638–45. https://doi.org/10.1001/jama.295.22.2638 PMID: 16772627

27. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014; 34(3):509–15. https://doi.org/10.1161/ATVBAHA.113.300156 PMID: 24554606

28. Sang X, Jiang Y, Wang W, Yan L, Zhao J, Peng Y, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens. 2013; 31(7):1465–71; discussion 71–2. https://doi.org/10.1097/HJH.0b013e328360ddf6 PMID: 24006040

29. Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Alloio B, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol. 2015; 173(5):665–75. https://doi.org/10.1530/EJE-15-0450 PMID: 26311088

30. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res. 2010; 42 (6):435–9. https://doi.org/10.1055/s-0029-1246189 PMID: 20119885

31. Huang XB, Tang WW, Liu Y, Hu R, Ouyang LY, Liu JX, et al. Prevalence of diabetes and unrecognized diabetes in hypertensive patients aged 40 to 79 years in southwest China. PLoS One. 2017; 12(2): e0170250. https://doi.org/10.1371/journal.pone.0170250 PMID: 28192474

32. Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Current Hypertension Reports. 2008; 10(6):496. https://doi.org/10.1007/s11906-008-0092-0 PMID: 18959838

33. Alam S, Kandasamy D, Goyal A, Vishnuhatla S, Singh S, Kharikiyan G, et al. High prevalence and a long delay in the diagnosis of primary aldosteronism among patients with young-onset hypertension. Clin Endocrinol. 2021; 94(6):895–903.